P/E ratio for DexCom (DXCM)
P/E ratio as of May 2024 (TTM): 134
According to DexCom's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 134.041. At the end of 2022 the company had a P/E ratio of 129.
P/E ratio history for DexCom from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 129 | -49.43% |
| 2021 | 254 | 258.6% |
| 2020 | 71.0 | -64.64% |
| 2019 | 201 | -341.22% |
| 2018 | -83.2 | -14.47% |
| 2017 | -97.3 | 27.09% |
| 2016 | -76.5 | -31.78% |
| 2015 | -112 | -38.86% |
| 2014 | -184 | 117.65% |
| 2013 | -84.3 | 390.1% |
| 2012 | -17.2 | 25.65% |
| 2011 | -13.7 | -0.7% |
| 2010 | -13.8 | 105.02% |
| 2009 | -6.73 | 387.32% |
| 2008 | -1.38 | -74.68% |
| 2007 | -5.45 | -5.47% |
| 2006 | -5.77 | 31.79% |
| 2005 | -4.38 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 11.0 | -91.81% | 🇺🇸 USA |
 Abbott Laboratories ABT | 35.0 | -73.87% | 🇺🇸 USA |
 Medtronic MDT | 31.6 | -76.43% | 🇮🇪 Ireland |
 Becton Dickinson BDX | 42.6 | -68.24% | 🇺🇸 USA |
 Edwards Lifesciences EW | 37.9 | -71.70% | 🇺🇸 USA |
 Tandem Diabetes Care
TNDM | -14.6 | -110.93% | 🇺🇸 USA |
 QuidelOrtho QDEL | 214 | 59.73% | 🇺🇸 USA |
 West Pharmaceutical WST | 47.4 | -64.67% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.